Long-Term Effects of AposTherapy in Patients with Osteoarthritis of the Knee: A Two-Year Followup
Table 2
Primary outcomes.
Outcome
Baseline
Mean difference ± SE (95% CI)
value
2 years
Mean difference ± SE (95% CI)
value
Time by treatment interaction (; significance)
WOMAC pain
Active
5.0 ± 2.8
−0.5 ± 1.0
1.9 ± 1.6
−4.9 ± 0.6
Control
5.5 ± 3.3
(−2.6, 1.6)
0.7
6.8 ± 2.0
(−6.2, −3.7)
<0.001*
= 16.8;
WOMAC stiffness
Active
5.5 ± 3.1
−0.1 ± 1.2
2.1 ± 1.7
−5.6 ± 0.6
Control
5.6 ± 3.3
(−2.4, 2.3)
0.9
7.7 ± 1.5
(−6.8, −4.3)
<0.001*
= 21.7;
WOMAC function
Active
4.9 ± 2.6
−0.9 ± 0.9
1.9 ± 1.3
−4.7 ± 0.5
Control
5.9 ± 2.5
(−2.8, 1.0)
0.3
6.6 ± 1.7
(−5.7, −3.6)
<0.001*
= 18.1;
ALF score
Active
35.5 ± 10.3
−5.8 ± 5.0
23.1 ± 6.4
−10.8 ± 2.5
Control
41.9 ± 22.3
(−2.8, 0.9)
0.3
33.9 ± 7.3
(−15.8, −5.8)
<0.001*
= 0.67;
WOMAC: Western Ontario and McMaster Osteoarthritis Index; ALF: Aggregated Locomotor Function. was considered statistically significant. Groups showed no significant differences at the baseline. Groups showed significant difference in all outcomes after two years. There was a significant difference in improvement over time between groups in all outcomes except for the ALF.
